#14DMedical™ The Future of Lung Health Investor Presentation 4DMedical Limited (4DX) Bell Potter Healthcare Conference November 2022#2Disclaimer This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (Company or 4DMedical). This presentation contains summary information about the Company, its subsidiaries and the entities, businesses and assets they own and operate (Group) and their activities current as of September 2022 unless otherwise stated and the information remains subject to change without notice. This presentation contains general background information and does not purport to be complete. No attempt has been made to independently verify the information contained in this presentation. Not an offer or financial product advice The Company is not licensed to provide financial product advice. This presentation is not and should not be considered, and does not contain or purport to contain, an offer or an invitation to sell, or a solicitation of an offer to buy, directly or indirectly any securities, to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement or recommendation to enter into, any contract whatsoever relating to any securities. This presentation is for information purposes only and is not a prospectus, product disclosure statement, pathfinder document for the purposes of section 734(9) of the Australian Corporations Act 2001 (Cth) (Corporations Act) or other offer document under Australian law or the law of any other jurisdiction. This presentation does not constitute an invitation to apply for or purchase Securities and does not include any application form for Securities. This presentation does not constitute an advertisement for an offer or proposed offer of Securities. Neither this presentation nor anything contained in it shall form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in, or refrain from engaging in, any transaction. Nothing in this presentation constitutes legal, financial, tax or other advice. Recipients of the presentation should conduct their own investigation, evaluation and analysis of the business and other data and information set out in the presentation. The distribution of this presentation in jurisdictions outside Australia may be restricted by law and you should observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this presentation may not be distributed or released in the United States. The Securities have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (U.S. Securities Act), or the securities laws of any state or other jurisdiction of the United States. Accordingly, the Securities may not be offered or sold, directly or indirectly, in the United States, unless they have been registered under the U.S. Securities Act (which the Company has no obligation to do or procure) or are offered or sold in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and applicable securities laws of any state or other jurisdiction of the United States. International Offer Restrictions This document does not constitute an offer of new ordinary shares ("New Shares") of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold, in any country outside Australia except to the extent permitted below. Bahamas The information in this document is intended solely for the designated recipient. It is not an offer to the public. No distribution of this information to anyone other than the designated recipient is intended or authorised. If You (or any person for whom You are acquiring the Securities) are in The Bahamas, this document has been given to you on the basis that You (and any such person): (a) are a licensee of the Securities Commission of The Bahamas, the Central Bank of The Bahamas or the Insurance Commission of The Bahamas; or (b) are an "accredited investor" (as defined in the Securities Industry Regulations, 2012 of The Bahamas), are deemed to be a non-resident for Bahamas exchange control purposes, will use funds from a non-Bahamas account to purchase the Securities, and acknowledge that there are restrictions on resales of the Securities in The Bahamas. 2#3Accelerating commercial progress Mar- Jul 22 31 Aug 22 30 Sep 22 19 Oct 22 4DMedical™ 25 Oct 22 Making significant progress across all areas of operations Major success as Vanderbilt 'burn pit' trial hits primary endpoint Continuing engagement with legislators, advocates and the VA 4DMedical progress towards full reimbursement in the U.S. 4DMedical release of CT LVASTM in Australia • XV Scanner unveiled at Prince of Wales Hospital in Sydney. • . US clinical pilot at Providence St Joseph commenced. Johns Hopkins COPD clinical trial results presented at ATS. Three-year national contract • signed with I-MED. • XV TechnologyⓇ validated through US clinical trials. • Facilitates commercial prospects in the US. • Supports significant opportunities with the already built VA and DoD relationships. Increase research benefiting veterans exposed to burn pits and toxic air. Collaborating with advocates, including Rosie Torres of Burn Pits 360. Enabling the PACT Act to reach its full potential, by scaling up VA evaluation and diagnosis processes without an invasive biopsy. AMA accepts XV LVASⓇ application to establish a new CPT code. Cat III code is a milestone for XV LVASⓇ to become a fully commercialised reimbursable product in the U.S. Expands 4DMedical's product visibility in the broader U.S. payer space. Strong news flow pipeline across all areas of operations • 4DMedical releases Computed Tomography Lung Ventilation Analysis Software (CT LVAS™). Expands patient accessibility by leveraging readily available CT hardware. Seamless integration enabled through the existing I-MED partnership. 4DMedical Limited | Investor Presentation | November 2022 3#4Market opportunity Respiratory diagnostics 4DMedical™#5Global market opportunity: USD $31.3 billion p.a. global spend • The market segmentation by the number of procedures. 4DMedical™ Market Opportunity by Country² Country Spend (USD) Procedures US 13,716M 73.5M X-ray Technology (67.05%) Others 4,964M 59.8M Procedures Expenditure 253m Germany 2,678M 20.3M USD $14.5 billion Japan 1,905M 22.8M China 1,851M 101.6M UK 1,351M 8.9M Pulmonary Function Tests (20.9%) France 1,191M 10.2M Spain 780M 8.4M Nuclear Medicine (0.4%) Computed Tomography (CT) (11.8%) Italy 681M 8.5M Canada 606M 8.0M South Korea 450M 6.8M Turkey 346M 16.1M Australia 285M 5.3M India 276M 25.3M Procedures Expenditure 78.9m Procedures 1.44m Procedures 44.5m USD $3.4 billion Expenditure USD $1.6 billion Expenditure USD $11.9 billion Switzerland 197M 1.2M Israel 69M 1.1M These four technologies account for the 3782 million respiratory diagnostics tests performed annually. 4DMedical Limited | Investor Presentation | November 2022 1. Frost and Sullivan Report 2020 2. Frost and Sullivan Report 2020 5#6U.S. market opportunity: Veterans' health in the United States 4DMedical™ • • The U.S. PACT Act is set to appropriate USD $280 billion in additional funding over ten years for affected veterans 3.5 million U.S. troops have been exposed to toxic burn pits since 1991. Recognition of the impact of Post-Deployment Respiratory Syndrome ('PDRS') and the need for a structured clinical response. Process for securing contracts with DoD¹ and VA² through NASA's SEWP³ program at a pre-agreed pricing structure of USD $171 per scan. VA to evaluate "emerging technology using existing x-ray imaging equipment to derive four-dimensional models of lung function" as part of the FY23 appropriations bill.4 4DMedical Limited | Investor Presentation | November 2022 1. U.S. Department of Defense 2. Veterans Affairs 3. Solutions for Enterprise-Wide Procurement 4. H.R.8294-Military Construction, Veterans Affairs, and Related Agencies Appropriations Act | 2023 | House of Representatives, 117th Congress) | 117-402.#7Respiratory diagnostics are failing us TAP Spirometry: 1846 CT: 1971 ME SPIROM 4DMedical Limited | Investor Presentation | November 2022 49-50 51-52 18 X-ray: 1895 49-50 51-52 53- 4DMedical™ Nuclear Medicine: 1971 7#8Respiratory diagnostics are failing us Spirometry: 1846 1D technology Accurate but insensitive 20.9% global market procedures Cost Advantages Limitations TAP ME SPIROM Spirometry: USD $72; Complete PFT: USD $750 Functional; Accurate; Zero dose; Non-invasive; Low cost (Spirometry) ⚫ Insensitive Non-specific Complete PFT expensive and time consuming Effort dependent (repeatability issues) Not applicable to all patient cohorts 4DMedical Limited | Investor Presentation | November 2022 4DMedical™ 8#9Respiratory diagnostics are failing us 4DMedical Limited | Investor Presentation | November 2022 4DMedical™ X-ray: 1895 2D technology Inexpensive but tells us very little about airflow 67.05% global market procedures Cost Advantages Limitations USD $120 (Average estimated) 2-dimensional scan; Ubiquitous; Relatively inexpensive; Low radiation dosage (0.1 mSv) ⚫ Measures structure rather than function . • Limited clinical value • Overlapping anatomy means features can be hidden and . be missed Poor record in screening applications 6#10Respiratory diagnostics are failing us CT: 1971 3D technology Sensitive, but expensive and high radiation dose 11.8% global market procedures 4DMedical Limited | Investor Presentation | November 2022 Cost Advantages: Limitations: 4DMedical™ USD $525 (Average estimated) 3-dimensional scan (can't miss features); Sensitive; High- resolution detail of images • Expensive: 4 times the cost of an X-ray • High radiation dose: 70 times an X-ray • High rate of false positives (~95% in NLCST vs 3% mortality for surgery) Measures structure rather than function • Very high rate of utilisation based on availability 10#11Respiratory diagnostics are failing us Cost VQ Scan: USD $1,503 (Average estimated) Advantages: Perfusion analysis capability; Only modality that can identify ventilation-perfusion mismatch; Importance in treating pulmonary embolism & hypertension 49-50 51-52 Limitations: High cost, poor resolution of outputs Time consuming (1 hour to complete) 49-50 51-52 • Use of dual radioactive particulate contrast agents raises toxicity concerns, • Expensive testing equipment needed • Complex to administer, requires expert analysis, onerous safety precautions 4DMedical Limited | Investor Presentation | November 2022 53- 4DMedical™ Nuclear Medicine: 1971 3D technology Measures both ventilation and perfusion but has significant limitations 0.4% global market procedures 11#12Introduction to XV Technology® 4DMedical™ Viewing - Coronal: XV Scan Layer - Airways - Vasculature - Ribs XV Scan: Specific Ventilation Less 0.0 0.5 1.0 More 15 2.0 3.75 Airways: Tube Diameter Smaller 0.0 7.5 11.25 Larger 15 Smaller 0.0 For demonstration purposes only. Not yet available for sale in the US. Vasculature: Tube Diameter 2.5 5 Larger 7.5 10 XV Technology™ Begin Acquisition Inspiration Expiration Complete Breath End Acquisition 4DMedical™ 12#13Advantages of existing modalities in a single platform 4DMedical Ventilation Report Scon Details Hine in Fit Reges Ce Wan Ventilation Report-Detailed Result video segional ventrabon vaulizations (through the breath phose R 四口 " beate Vot 4DMedical Limited | Investor Presentation | November 2022 الى 4DMedical™ Functional insight of spirometry at a regional level Comparable radiation dose to X-ray High-detail resolution of a CT scan Improved clinical outcomes Faster, more efficient testing using existing hardware $ Competitive pricing below incumbent technologies 13#14Demonstrating clinical application 4DMedical™#15Demonstrating clinical utility: Reliability & repeatability Age 30's Sex Male Summary Indications Healthy male with no signs of disease . XV LVASⓇ validated assessment of regional lung function. XV TechnologyⓇ proved the reliable repeatability of findings. Baseline a • XV Technology enabled the quantification of regional ventilation defects. Follow-up scan (3 months) . Effective monitoring of disease and treatment effects. Clinical Observations • The lung fields are clear without any marked lesions or diseases. • . The lung fields are clear without any marked lesions or diseases. Healthy lungs with consistent green and blues, indicative of healthy lung function as expected with a healthy 30-year-old. 4DMedical Limited | Investor Presentation | November 2022 4DMedical™ TV VH VDP 0.68 42.8 13.0 a 0 4 TV VH VDP 0.77 44.5 13.8 15#16Demonstrating clinical utility: Silicosis Age 36 Sex Male Indications Novel treatment for a Severe Progressive Silicosis related Occupational Lung Disease Summary • • At baseline, there are advanced changes of chronic, complicated silicosis as marked by nodular coalescence and fibrosis in the apical regions bilaterally, leading to progressive massive fibrosis. No significant structural changes are seen after treatment (on CT). Following treatment, there are functional improvements in all inspiratory metrics visible on XV LVAS®. Notably, the right apical region with areas of relative underventilation (red shading) has markedly improved to average ventilation (green shading) following treatment. Clinical Observations . Quantifiable, regional improvements in inspiratory function have been observed following treatment for lung disease, which assists the clinician in monitoring treatment effectiveness. In comparison, serial chest CTs showed no significant change following this treatment. 4DMedical Limited | Investor Presentation | November 2022 Baseline TV VH VDP 0.50 54.5 17.3 Follow-up scan (3 months post-treatment) TV 0.59 VH 47.3 VDP 13.8 4DMedical™ 16#17Demonstrating clinical utility: COPD Age 60 Sex Male Indications Prior biologics therapeutic for re-current exacerbation of moderate obstructive lung disease Baseline TV VH XV LVAS 0.69L 60.8% VDP 18.1% Summary • • SOB for further investigation. At baseline CT was unremarkable. Placed on biologics for history of exacerbation. Following Tx, there are functional improvements in regional ventilation indices (reduced VH and VDP). Notably, appearance of improved. ventilation, specifically in the dependent areas of the right and left lungs. Corresponding with patient reported improvement in symptoms. Clinical Observations Structural CT Follow-up scan (5 Months Post-Treatment) • Improved symptoms demonstrated a clinical correlation with improvements in regional ventilation function. Continued therapy with novel biologics. Functional assessment of regional ventilation assists in tracking response to therapy and management. Structural CT XV LVAS TV 0.7L VH 47.0% 4DMedical Limited | Investor Presentation | November 2022 4DMedical™ VDP 13.4% 17#18Demonstrating clinical utility: Long Covid-19 Age 52 Indications Sex Female Long Covid symptoms Baseline Chest CT: Acute COVID- 19 infection 1400KV 226mA Tit 0.0de 140.0KV 247mA 4DMedical™ Summary • • Patient hospitalised for COVID-19. • • During admission chest CT observed peripheral ground-glass and consolidative pulmonary opacities. (no XV LVASⓇ imaging was captured). Following Tx and discharge from hospital, the patient continued to display symptoms of shortness of breath, cough and dyspnea on exertion. Following physician consultation, a follow-up CT and 4DMedical XV LVASⓇ were prescribed. C Structural CT: Peripheral ground-glass and consolidative pulmonary opacities Follow-up scan (3 Months Post Acute COVID -19 infection) PO 512x512 om: 127 % lossless) W499 L-600 Clinical Observations • Follow-up CT observed a resolution of the peripheral ground glass and consolidative pulmonary opacities. • XV LVASⓇ highlighted heterogeneity between the left and right lung regional performance. • Additionally, previous areas of ground glass and consolidative pulmonary opacities displayed under ventilation specific to that region of the lung. 4DMedical Limited | Investor Presentation | November 2022 120.0 THE 0.00% 512612 127% Companion lossless) Taco 17 Imm 128 136 18#19Demonstrating clinical utility: Assessment of hiatal hernia Age 69 Sex Female • Summary Indications History of COVID-19 • Gastric esophageal reflux disease Recurrent chest infections • CT imaging indicated a large hiatal hernia. XV LVASⓇ demonstrated a greater functional reduction in ventilation than expected from CT changes. Clinical Observations • • XV LVAS® Relative reduced ventilation in the left lower zone due to mass effect from hernia (non-obstructive atelectasis). Not fully appreciated on CT scan. 4DMedical Limited | Investor Presentation | November 2022 Hiatal Hernia 4DMedical™ 19#20Commercialisation 4DMedical™#21Commercialisation: Two pillar strategy Clinical trials 3!! Research partners delivering the body of scientific evidence for clinical use Commercial pilots 4DMedical™ Physicians gaining familiarity with technology and business case for clinical adoption Who Why • Eminent researchers and leading medical institutes Diagnostics, treatment efficacy, monitoring, disease progression and more Who • Respiratory specialists, imaging centres, hospitals Why . • Assess holistic regional lung function for patient management - ventilation and perfusion Alternative to nuclear medicine Outcome: ⚫ Scientific investigation into case applications ⚫Publishing manuscripts and presenting research to industry Study design: Full scientific method per researcher Outcome: ⚫Clinical familiarisation • Clinical and business case for technology adoption Pilot design: Tiered per facility & physician interest 4DMedical Limited | Investor Presentation | November 2022 21#22Commercialisation: Johns Hopkins COPD trial result • Has the capability of assessing regional ventilation defects, which is critical to optimising therapies. Is a repeatable lung assessment tool in a cohort of COPD patients. • Illustrates distribution of airflow within the lungs, corresponding with COPD severity. Mean Specific Ventilation (a.u.) Ventilation Heterogeneity/ Ventilation Heterogeneity By Disease Severity 200 400 600 800 1,000 1,200 Inspiration Expiration 1 2 GOLD score 4DMedical Limited | Investor Presentation | November 2022 Patient 2 Patient 1 Visit 1 RIGHT LEFT UPPER RIGHT Normalized Specific Ventilation 0 RIGHT 3 4 Normalized Specific Ventilation 0 R Upper MIDDLE Middle 4DMedical™ Visit 2 Upper LEFT Middle Lower Lower LOWER LEFT UPPER RIGHT LEFT UPPER MIDDLE LOWER Normalized Specific Ventilation 1 2 R R L MIDDLE R L LOWER 22#23Commercialisation: Burn pit trial results • PDRS is not detectable by Spirometry, X-ray or CT only via surgical biopsy. XV clinical trial outputs displaying ventilation variation • 4DMedical's XV TechnologyⓇ detects the presence of constrictive bronchiolitis ('CB'). • Quantitative scores identify the differences between Veterans with constrictive bronchiolitis and healthy controls. XV Technology® confirmed the diagnosis of CB. Ongoing assessment of the Vanderbilt clinical trial data is expected to lead to publication. 4DMedical Limited | Investor Presentation | November 2022 HEALTHY XV Technology® confirmed the diagnosis of CB DISEASED 4DMedical™ 23#24Progressing clinical trials Completed Studies Imaging Complete Pneumonitis Cedars Sinai XV LVASⓇ COPD Johns Hopkins XV LVAS® Patient Stages Recruitment Lung Transplant Duke University XV LVASⓇ Imaging in Progress BLVR University of Miami XV LVAS® PH COPD Cleveland Clinic Oregon Health & Science University VQTM CB (PDRS) Lung Transplant COPD Vanderbilt University Alfred Hospital Melbourne XV LVASⓇ XV LVASⓇ Imaging in Progress Imaging Complete Completed Study 4DMedical Limited | Investor Presentation | November 2022 XV LVASⓇ BLVR 4DMedical™ Paediatric CF Johns Hopkins XV LVASⓇ COPD Vanderbilt University Temple University University of Miami XV LVASⓇ XV LVASⓇ XV LVASⓇ 24#25CT LVASTM product release in Australia 4DMedical™ • CT LVASTM provides an similar report to XV LVASⓇ but utilises widely available CT imaging infrastructure (instead of X-ray). • Provides clinicians and patients with the benefits of XV Technology®, significantly growing the accessibility of functional lung imaging for Australians living with lung disease. Uses existing CT hardware and easily integrates into clinical workflows across the I-MED network. • CT LVAS™ will position 4DMedical to leverage I-MED's extensive existing CT network to provide greater patient access. • I-MED agreement to drive revenue for the Company, as it creates a framework for the rapid commercialisation of the CT LVASTM product in Australia. 4DMedical Limited | Investor Presentation | November 2022 22#26Commercialisation: Penetration of Australia has commenced I-MED Radiology Network Comprehensive care. Uncompromising quality. • • . 4DMedical™ Three-year contract signed with Australia's largest radiology provider I-MED with a 250-site network. Successfully rolled out the Company's XV Technology® across nine sites spanning Australia and Tasmania. Release of CT LVASTM to accelerate rollout. Used to assist in diagnosis, the unique capability and low-dosage modality developed is proving particularly useful as a surveillance tool in understanding lung disease. 4DMedical ALHI 4DMedical XVScanner 4DMedical 4DMedical Limited | Investor Presentation | November 2022 MRFF provided AUD $28.9 million in funding, with AUD $15.0 million yet to be received. First XV Scanner installed at the Prince of Wales Hospital. 26#27Commercialisation: U.S. growth and opportunities THE WHITE HOUSE PARTMENT OF VETERANS U.S. Department VA of Veterans Affairs • • • 4DMedical™ The PACT Act legislation removes the burden of proof on veterans and provides an additional USD $280 billion to be spent over 10 years. Ensuring veterans get the care they need includes ensuring that they are screened for toxic exposure.¹ Streamlined process for securing contracts with the DoD and VA through NASA's SEWP program, including a pre-agreed pricing structure of USD $171 per scan. The VHA FY23 budget is USD $301.4 billion², operating 1,255 healthcare facilities and serving 19.2 million veterans across the United States. Providence St. Joseph Health • . Providence St. Joseph, is one of 52 hospitals with 1085 clinics³ in the world-class Providence Healthcare network. XV LVAS® software is used to assist in screening for multiple respiratory conditions, including Chronic Obstructive Pulmonary Disease and long-COVID. 4DMedical Limited | Investor Presentation | November 2022 1. https://www.whitehouse.gov/briefing-room/statements-releases/2022/08/02/fact-sheet-pact-act-delivers-on-president-bidens-promise-to-americas-veterans/ 2. FY 2023 Budget Submission, 'Budget in Brief: Overview', 2023 Congressional Submission, [page BiB-1] (March 2022) <https://www.va.gov/budget/products.asp> 3. Providence, "About Us, (Website accessed 22/08/2022). < https://www.providence.org/about> 27#28Product pipeline 4DMedical™#29An evolving product pipeline TM 4DMedical 4DMedical software offering Current product release XV LVASⓇ (ventilation) CT LVASTM (ventilation) Image acquisition modality 4DMedical Limited | Investor Presentation | November 2022 4DMedical X-ray (existing hospital & radiology hardware) XV Scanner (4DMedical hardware) CT:VQ (ventilation/perfusion) CT (existing hospital & radiology hardware) 4DMedical™ 29#30An evolving product pipeline The simplicity of offering (Ventilation or Perfusion) with the flexibility of distribution Fluoroscopy (X-ray) 4DMedical software offering Computed Tomography (CT) XV Scanner (XVD) Image acquisition modality Ventilation (XV) XV LVASⓇ 1 Perfusion (VQ) 4DMedical Limited | Investor Presentation | November 2022 CT LVASTM CT based VQ 4 2 Rapid XV LVAS® 3 4DMedical™ 30#31Experienced Team 4DMedical™#32Board of directors Advisory board 4DMedical™ BRUCE RATHIE Non-Executive Chairman Experienced lawyer, investment banker and company director; currently Non- Executive Director of PolyNovo Limited (PNV.ASX) and Netlinkz Limited (NET.ASX). Dr ANDREAS FOURAS PhD Managing Director and Chief Executive Officer Award-winning aerospace engineer and innovator responsible for the conception and development of 4DMedical's core technologies. LIL BIANCHI Non-Executive Director; Chair, Audit & Risk Committee Experienced contributor of business transformations for US listed technology companies with a beneficial technology product expertise in Al and SaaS offerings. Dr ROBERT A. FIGLIN MD Non-Executive Director Globally recognised leader in genitourinary and thoracic oncology, as well as Editor of the Kidney Cancer Journal and Spielberg Family Chair in Hematology/Oncology at Cedars Sinai. Dr SAM HUPERT MBBS Advisory Board Member Co-founder and Chief Executive Officer of Pro Medicus Ltd (PME.ASX) which develops and markets health imaging software primarily for radiologists in the U.S., Europe and Australia. Dr RAYMOND CASCIARI MD Advisory Board Member Former Chief Medical Officer at St. Joseph Hospital in Orange, CA with over 40 years' experience in Pulmonary Disease, Internal Medicine and Intensive Care Medicine. JULIAN SUTTON Non-Executive Director Chartered Financial Analyst who began his career as an actuarial analyst in Melbourne before moving into funds management with Schroders and Credit Suisse in London. JOHN LIVINGSTON Executive Director Founding partner of ASX-listed Integral Diagnostics (IDX.ASX) and an industry leader in the implementation of PACS and RIS in radiological settings. EVONNE COLLIER Non-Executive Director; Chair, Remuneration & Nomination Committee Experienced in board appointments (ASX, private, publicly unlisted) with an executive background in marketing, innovation/tech and commercial roles. Prof BRUCE THOMPSON PhD Advisory Board Member Board member and past president of the Thoracic Society of Australia and New Zealand; currently Dean of the School of Health Sciences at the University of Melbourne, and a former Head of Physiology Services at the Alfred Hospital. 4DMedical Limited | Investor Presentation | November 2022 32#33Experienced: Executive team 4DMedical™ Dr ANDREAS FOURAS PhD CEO Award-winning aerospace engineer and innovator responsible for the conception and development of 4DMedical's core technologies. RACHAEL TENKATEN Chief of Staff Aerospace engineer with experience gained through transformative biomedical, aerospace and defence technology projects. Dr AIDAN JAMISON PhD Senior Vice President Engineering With a PHD in medical imaging and a Masters of Law (IP), Aidan is an accomplished technical expert leading the R&D of the Company's product pipeline. NICHOLE MURRAY Vice President Regulatory Affairs & Quality Assurance Over 20 years of experience in regulatory affairs and quality assurance functions in the pharmaceutical and medical device industries. Dr JASON KIRKNESS PhD Senior Vice President Medical & Clinical Affairs Over 20 years' training and experience in pulmonary physiology and sleep medicine, including faculty position at Johns Hopkins and global industry leaders. BETH PLUNKETT Corporate Counsel Accomplished commercial lawyer with expertise spanning corporate, finance, technology licensing and research collaboration contracts. Dr JON DUSTING PhD Chief Research Officer Demonstrated capabilities in translating ambitious research vision into disruptive biotechnology products, including the MRFF-funded XV Scanner. SIMON GLOVER Chief Finance Officer Experienced ASX-listed MedTech company CFO with significant corporate experience in relation to commercialisation, and a track record of driving revenue growth. 4DMedical Limited | Investor Presentation | November 2022 33#34Executive Summary 4DMedical™#35Executive Summary · • Clinically validated technology: richer diagnostic value, safer, lower cost. Significant global market with attractive growth opportunities in the core U.S. market. Top tier relationships: clinical and commercial Massively scalable SaaS business model. Strong pipeline protected by a strong (and growing) IP portfolio. Highly experienced Board of Directors and senior management. 4DMedical Limited | Investor Presentation | November 2022 4DMedical™ 35#36APPENDICES 4DMedical™#37Product pipeline (in detail) 4DMedical™#38An evolving product pipeline OFFERING DISTRIBUTION Fluoroscopy (X-ray) Computed Tomography (CT) Ventilation XV LVAS® Perfusion X:VQ • Ventilation refers to airflow into and out of the alveoli. Perfusion refers to the flow of blood to alveolar capillaries. 4DMedical Limited | Investor Presentation | November 2022 CT:V CT:VQ 4DMedical™ XV Scanner (XVD) Rapid XV LVASⓇ Rapid VQ 38#39An evolving product pipeline 4DMedical™ 4DMedical Current product software offering release XV LVASⓇ (ventilation) CT LVASTM (ventilation) Image acquisition modality 4DMedical Limited | Investor Presentation | November 2022 40Medical X-ray (existing hospital & radiology hardware) XV Scanner (4DMedical hardware) 11 F 4DMedical™ CT:VQ (ventilation/perfusion) CT (existing hospital & radiology hardware) 39#40• . An evolving product pipeline The simplicity of offering (Ventilation or Perfusion) with the flexibility of distribution 4Dimensional Data • High resolution . Low Dose Software offering 4DMedical Limited | Investor Presentation | November 2022 Image acquisition modality Fluoroscopy Computed Tomography Modality (X-ray) (CT) Ventilation Perfusion XV LVASⓇ 4DMedical™ 40#41• . An evolving product pipeline The simplicity of offering (Ventilation or Perfusion) with the flexibility of distribution 3Dimensional Data · High accessible • Same output as XV LVASⓇ Software offering 4DMedical Limited | Investor Presentation | November 2022 Image acquisition modality Fluoroscopy Modality (X-ray) Computed Tomography (CT) Ventilation XV LVASⓇ CT LVASTM Perfusion I 41 4DMedical™#424DMedical™ • . ● An evolving product pipeline The simplicity of offering (Ventilation or Perfusion) with the flexibility of distribution Ventilation and Perfusion 3Dimensional Data • Highly accessible • No contrast required Image acquisition modality Fluoroscopy Computed Tomography Modality (X-ray) (CT) Software offering 4DMedical Limited | Investor Presentation | November 2022 Ventilation XV LVASⓇ CT LVASTM Perfusion CT:VQ 42#43• An evolving product pipeline The simplicity of offering (Ventilation or Perfusion) with the flexibility of distribution Software offering Fluoroscopy (X-ray) Ventilation XV LVASⓇ Perfusion 4DMedical Limited | Investor Presentation | November 2022 1 Image acquisition modality Computed Tomography (CT) XV Scanner (XV) CT LVASTM CT based VQ 4 2 Rapid XV LVAS® 3 4DMedical™ 43#44• An evolving product pipeline The simplicity of offering (Ventilation or Perfusion) with the flexibility of distribution Software offering Fluoroscopy (X-ray) Image acquisition modality Computed Tomography (CT) XV Scanner (XVD) Ventilation XV LVASⓇ CT LVASTM Rapid XV LVAS® Perfusion X-ray based VQ CT based VQ 4DMedical Limited | Investor Presentation | November 2022 Rapid X-ray based VQ 4DMedical™ 44#45Product pipeline (in detail) 4DMedical™#46An evolving product pipeline Stage Research & Development CT LVASTM CT:VQ XV Scanner Regulatory & Review CT LVASTM CT:VQ XV Scanner Commercialisation XV LVASⓇ CT LVASTM CT:VQ XV Scanner 4DMedical™ CY2022 CY2023 CY2024 CY2025 4DMedical Limited | Investor Presentation | November 2022 I 46#474DMedical™ The Future of Lung Health Corporate CFO Simon Glover [email protected] Administration Company Secretary Melanie Leydin [email protected] Media Enquiries TCN Julia Maguire [email protected]